InSilicoTrials Appoints Mark Lovern as Chief Platform Officer
Move marks commitment to leading the frontier of AI-driven innovation and simulation in life sciences, company says.
InSilicoTrials revealed that it has officially hired Mark Lovern to be its new chief platform officer. In his new role, Lovern will focus on combining his scientific knowledge with artificial intelligence (AI), machine learning (ML) and simulation technologies, along with an in-depth understanding of regulatory science, to drive the development of the InSilicoTrials.com platform and position it as a catalyst for hyper-accelerating life science R&D.
"Mark's extensive experience and mastery in model-informed drug development align seamlessly with our vision of revolutionizing the life sciences industry," said Luca Emili, CEO, InSilicoTrials, in a company press release. "His prior achievements, combined with our groundbreaking AI and simulations platform, will surely take our capabilities to unprecedented heights.”
Reference: Mark Lovern Joins InSilicoTrials as Chief Platform Officer. PR Newswire. October 17, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/mark-lovern-joins-insilicotrials-as-chief-platform-officer-301958909.html
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
